Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Short Interest Update

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) saw a large growth in short interest during the month of January. As of January 15th, there was short interest totalling 6,680,000 shares, a growth of 12.5% from the December 31st total of 5,940,000 shares. Based on an average trading volume of 975,100 shares, the short-interest ratio is presently 6.9 days.

Analyst Ratings Changes

Several equities research analysts have recently commented on CPRX shares. HC Wainwright boosted their price target on shares of Catalyst Pharmaceuticals from $30.00 to $35.00 and gave the company a “buy” rating in a report on Friday, January 10th. StockNews.com downgraded Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 11th. Truist Financial increased their price target on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a research report on Monday, November 11th. Stephens initiated coverage on shares of Catalyst Pharmaceuticals in a report on Monday, November 18th. They set an “overweight” rating and a $35.00 price target on the stock. Finally, Bank of America reaffirmed a “buy” rating and set a $30.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $32.86.

Insider Transactions at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, Director Molly Harper sold 17,500 shares of the stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $22.00, for a total value of $385,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Steve Miller sold 50,000 shares of Catalyst Pharmaceuticals stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $21.93, for a total transaction of $1,096,500.00. Following the completion of the transaction, the insider now directly owns 686,996 shares of the company’s stock, valued at $15,065,822.28. The trade was a 6.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 79,500 shares of company stock valued at $1,754,140. Insiders own 11.00% of the company’s stock.

Institutional Investors Weigh In On Catalyst Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in CPRX. abrdn plc bought a new position in Catalyst Pharmaceuticals in the 4th quarter worth approximately $10,115,000. Jane Street Group LLC increased its holdings in Catalyst Pharmaceuticals by 245.4% during the third quarter. Jane Street Group LLC now owns 401,908 shares of the biopharmaceutical company’s stock worth $7,990,000 after buying an additional 285,564 shares during the last quarter. Walleye Capital LLC bought a new stake in Catalyst Pharmaceuticals in the 3rd quarter valued at $4,936,000. AQR Capital Management LLC lifted its holdings in Catalyst Pharmaceuticals by 87.1% during the 2nd quarter. AQR Capital Management LLC now owns 488,386 shares of the biopharmaceutical company’s stock worth $7,565,000 after purchasing an additional 227,321 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its stake in shares of Catalyst Pharmaceuticals by 146.8% in the third quarter. Allspring Global Investments Holdings LLC now owns 366,444 shares of the biopharmaceutical company’s stock valued at $7,285,000 after buying an additional 217,956 shares during the period. 79.22% of the stock is owned by hedge funds and other institutional investors.

Catalyst Pharmaceuticals Price Performance

Shares of NASDAQ CPRX traded up $0.06 during midday trading on Monday, hitting $22.62. 1,218,631 shares of the company’s stock were exchanged, compared to its average volume of 1,468,708. Catalyst Pharmaceuticals has a twelve month low of $13.12 and a twelve month high of $24.64. The firm has a market cap of $2.70 billion, a P/E ratio of 19.17, a PEG ratio of 2.25 and a beta of 0.80. The stock’s 50 day moving average price is $22.01 and its 200-day moving average price is $20.79.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.